world-biomarkers-pharma-biotech-2017-posters

22 / 61

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 78
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Gene expression profiling reveals novel candidate genetic biomarkers of ovarian carcinoma prognosis
and metastasis
Radka Vaclavikova1,5, Katerina Elsnerova1,5, Marie Ehrlichova 1,5, Lukas Rob2, Martin Hruda2, Petr Skapa3, Alena Bartakova4, Jiri Bouda4 and Pavel
Soucek1,5
1National Institute of Public Health, Czech Republic
2Vinohrady University Hospital, Czech Republic
3Motol University Hospital, Czech Republic
4University Hospital in Pilsen- Charles University, Czech Republic
5Charles University, Czech Republic
Epithelial ovarian cancer (EOC) has the highest mortality among gynecological carcinomas. Given the diversity in responses
to the therapy, there is a need for identification of reliable biomarkers of prognosis, progression and prediction of EOC
therapy outcome. The aim of our study was (i) to explore differences in expression of 94-gene panel connected to drug transport
(ABC, SLC transporters), metabolism and cell cycle regulation in a set of primary EOC tissues (n=60), intraperitoneal
metastases (n=29) and control ovarian tissues (n=14) as well as in a validation set of EOCs (n=57) using quantitative real-time
PCR; (ii) to investigate associations of gene expression level with prognosis, development of metastasis and progression-free
survival of EOC patients. Different gene expression profiles were found in ovarian carcinomas when compared with controls.
Expression of ABCA7 significantly increased and that of ESR2 decreased in the order control ovarian tissues - primary EOCs
– EOC metastases. The most important associations between gene expression and clinicopathological data were found for
membrane transporters (ABCA2/9/10, ABCG2, SLC16A14 ) and cell cycle regulators (PLK1, CIT, PRC1 ). Transporters from the
ABCA family, ABCG2 and ESR2 are involved mainly in lipid metabolism, membrane transport and cell proliferation. These
processes are thus probably important for EOC progression. In conclusion, we have proposed novel genetic biomarkers of
ovarian carcinoma prognosis and progression potentially useful as therapeutic targets.
Biography
Radka Vaclavikova has completed her PhD from Charles University in Prague, CZ and conducted her Post-doctoral studies in cooperation with Faculty of
Medicine, University of Oslo, Norway. She is a Principal Investigator in Toxicogenomics Unit, National Institute of Public Health in Prague, CZ and in Laboratory
of Pharmacogenomics, Biomedical Center in Pilsen, CZ. She has published 34 papers in impacted journals (450 citations, H Index 12) and serves as a Mentor of
doctoral studies under Faculty of Medicine, Charles University in Prague.
Radka Vaclavikova et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110